Stocks News

LAST PRICE
103.0900
TODAY'S CHANGE (%)
Trending Up0.8600 (0.8412%)

Bid / Lots
97.5700/ 1
Ask / Lots
106.1700/ 1
Open / Previous Close
101.8400 / 102.2300
Day Range
Low 101.0050
High 103.5400
52 Week Range
Low 49.2400
High 112.1250
Volume
71,381
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Sep 6, 2024
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI(R) (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy, from 9:20AM ET on Friday Sep 06, 2024 by Dow Jones
  9:20AM ET on Friday Sep 06, 2024 by Dow Jones
  Companies Mentioned: LGND
  
  the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  
  View source version on businesswire.com: https://www.businesswire.com/news/home/20240906026028/en/
Aug 20, 2024
- Ligand to Present at H.C. Wainwright 26(th) Annual Global Investment Conference, from 9:00AM ET on Tuesday Aug 20, 2024 by Dow Jones
  9:00AM ET on Tuesday Aug 20, 2024 by Dow Jones
  Companies Mentioned: LGND
  JUPITER, Fla.--(BUSINESS WIRE)--August 20, 2024--
  Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the H.C. Wainwright 26(th) Annual Global Investment Conference in New York on Tuesday, September 10, 2024, at 8:30 a.m. Eastern Time.
Aug 13, 2024
- Ligand Pharmaceuticals Insider Sold Shares Worth $1,797,133, According to a Recent SEC Filing, from 5:28PM ET on Tuesday Aug 13, 2024 by MT Newswires
  5:28PM ET on Tuesday Aug 13, 2024 by MT Newswires
  Companies Mentioned: LGND
  05:28 PM EDT, 08/13/2024 (MT Newswires) -- Matthew E Korenberg, President & COO, on August 09, 2024, sold 18,245 shares in Ligand Pharmaceuticals (LGND) for $1,797,133. Following the Form 4 filing with the SEC, Korenberg has control over a total of ...

Sep 9, 2024
- --Kempen Initiates Coverage on Immunocore Holdings With Buy Rating, $70 Price Target, from 7:50AM ET on Monday Sep 09, 2024 by MT Newswires
  7:50AM ET on Monday Sep 09, 2024 by MT Newswires
  Companies Mentioned: IMCR
Sep 5, 2024
- Ocular Therapeutix(TM) to Present at September Retina Meetings, from 7:30AM ET on Thursday Sep 05, 2024 by GlobeNewswire
  7:30AM ET on Thursday Sep 05, 2024 by GlobeNewswire
  Companies Mentioned: OCUL
- Ocular Therapeutix(TM) to Present at September Retina Meetings, from 7:30AM ET on Thursday Sep 05, 2024 by Dow Jones
  7:30AM ET on Thursday Sep 05, 2024 by Dow Jones
  Companies Mentioned: OCUL
Sep 4, 2024
- Ocular Therapeutix(TM) to Present at Two Investor Conferences in September, from 7:30AM ET on Wednesday Sep 04, 2024 by GlobeNewswire
  7:30AM ET on Wednesday Sep 04, 2024 by GlobeNewswire
  Companies Mentioned: OCUL
- Ocular Therapeutix(TM) to Present at Two Investor Conferences in September, from 7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones
  7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones
  Companies Mentioned: OCUL
- DJ Avadel Pharmaceuticals Price Target Maintained With a $22.00/Share by Needham, from 6:44AM ET on Wednesday Sep 04, 2024 by Dow Jones
  6:44AM ET on Wednesday Sep 04, 2024 by Dow Jones
  Companies Mentioned: AVDL
Sep 3, 2024
- Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ(TM) Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII), from 8:00AM ET on Tuesday Sep 03, 2024 by GlobeNewswire
  8:00AM ET on Tuesday Sep 03, 2024 by GlobeNewswire
  Companies Mentioned: AVDL
- Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ(TM) Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII), from 8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
  8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
  Companies Mentioned: AVDL
- Harrow to Present at Three Investor Conferences in September in New York, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
  7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
  Companies Mentioned: HROW
Aug 29, 2024
- DJ Harrow Price Target Maintained With a $50.00/Share by B. Riley Securities, from 10:42AM ET on Thursday Aug 29, 2024 by Dow Jones
  10:42AM ET on Thursday Aug 29, 2024 by Dow Jones
  Companies Mentioned: HROW

Ligand Pharmaceuticals Inc
NASDAQ:LGNDUnited States

Search Criteria

Sep 6, 2024

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI(R) (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy, from 9:20AM ET on Friday Sep 06, 2024 by Dow Jones

Aug 20, 2024

Ligand to Present at H.C. Wainwright 26(th) Annual Global Investment Conference, from 9:00AM ET on Tuesday Aug 20, 2024 by Dow Jones

Aug 13, 2024

Ligand Pharmaceuticals Insider Sold Shares Worth $1,797,133, According to a Recent SEC Filing, from 5:28PM ET on Tuesday Aug 13, 2024 by MT Newswires

Peers Headlines

Sep 9, 2024

--Kempen Initiates Coverage on Immunocore Holdings With Buy Rating, $70 Price Target, from 7:50AM ET on Monday Sep 09, 2024 by MT Newswires

Sep 5, 2024

Ocular Therapeutix(TM) to Present at September Retina Meetings, from 7:30AM ET on Thursday Sep 05, 2024 by GlobeNewswire

Ocular Therapeutix(TM) to Present at September Retina Meetings, from 7:30AM ET on Thursday Sep 05, 2024 by Dow Jones

Sep 4, 2024

Ocular Therapeutix(TM) to Present at Two Investor Conferences in September, from 7:30AM ET on Wednesday Sep 04, 2024 by GlobeNewswire

Ocular Therapeutix(TM) to Present at Two Investor Conferences in September, from 7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones

DJ Avadel Pharmaceuticals Price Target Maintained With a $22.00/Share by Needham, from 6:44AM ET on Wednesday Sep 04, 2024 by Dow Jones

Sep 3, 2024

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ(TM) Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII), from 8:00AM ET on Tuesday Sep 03, 2024 by GlobeNewswire

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ(TM) Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII), from 8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones

Harrow to Present at Three Investor Conferences in September in New York, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones

Aug 29, 2024

DJ Harrow Price Target Maintained With a $50.00/Share by B. Riley Securities, from 10:42AM ET on Thursday Aug 29, 2024 by Dow Jones